Xiangzhao Li

Xiangzhao Li

Auto-generated profile, based on publicly available information

Xiangzhao Li

Department of Pathology, Nanfang hospital, Southern Medical University, Guangzhou 510515, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
XWXiaolei Wei
Xiaolei Wei
MXMeng Xu
Meng Xu
YWYongqiang Wei
Yongqiang Wei
FHFen Huang
Fen Huang
TZTong Zhao
Tong Zhao
BYB Hilda Ye
B Hilda Ye
Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

8 August 2018 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
JXJun Xiao
Jun Xiao
YHYong Hu
Yong Hu
KTKai-Ying Tang
Kai-Ying Tang
TTTahsin Tarik Torsha
Tahsin Tarik Torsha
YXYu Xu
Yu Xu
ZSZhan-Jun Shi
Zhan-Jun Shi

30 November 2020
Verified
Journal Article
Closed access
XLXiangzhao Li
Xiangzhao Li
HLHuanjiao Liu
Huanjiao Liu
MLMinyi Liang
Minyi Liang
HCHuihui Chen
Huihui Chen
LLLi Liang
Li Liang